VivoSim logs first China commercial orders for NAMkind GI toxicology, efficacy testing services

VivoSim Labs Inc

VivoSim Labs Inc

VIVS

0.00
  • VivoSim reported first commercial sales in mainland China for its NAMkind toxicology screening and GI efficacy testing services.
  • Two paid engagements signed with a Shanghai-based oncology biotech, plus a Chengdu-based pharmaceutical company, via local distributor Tekon.
  • Orders cover GI toxicology screening, plus GI efficacy profiling for candidate molecules in oncology, plus other disease areas.
  • Company said the two orders represent a meaningful share of contracted revenue to date, marking an Asia-Pacific expansion milestone.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.